Technologies

The technology, developed by CNR-ICB, is based on an innovative bioprocess called "Caphnophilic (CO2-requiring) Lactic Fermentation (CLF)”, developed in the hyperthermophilic bacterium Thermotoga neapolitana (EP patent: EP2948556B1), which allows the production of "green" hydrogen and capture and valorization of CO2 in L -lactic acid (98% e.e.).

Our treatment demonstrated the ability to kill metastatic human melanoma cells, for which there are very few effective therapeutic approaches. Use of a specific Essential Oil (EO) to inhibit the replication of human metastatic melanoma cells. This EO can be used both for direct application to the skin, and administered by mouth to reach both primary and metastatic melanomas.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.